1. Home
  2. NEWS RELEASE
  3. Shiseido Marks the 30th Anniversary of Joint Research in Dermatology

Sep. 18, 2019

Publisher: Shiseido

R&D/Supply Network

Shiseido Marks the 30th Anniversary of Joint Research in Dermatology

-Another 6 years of alliance with US Dermatology Laboratory-

Shiseido Company, Limited (“Shiseido”) has agreed on Tuesday, September 17, 2019 to extend for a further six years its research alliance with the dermatological laboratory CBRC (Cutaneous Biology Research Center), established by Harvard Medical School Dermatology Research Labs, and Massachusetts General Hospital in Boston, Massachusetts, USA. This new agreement will be effective July 2021 through June 2027.

The CBRC was founded in 1989, and is known as a world-class laboratory in the field of dermatology. Shiseido has been collaborating for 30 years with the CBRC as a pioneer of open innovation pursuing unprecedented research collaboration with external organizations both nationally and internationally. Many of the cutting-edge research results are utilized in our product research and development.

Going forward, to achieve our corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD,” Shiseido will continue joint research with the CBRC and create cutting-edge value through research in dermatology including ultraviolet rays and aging, as well as development of innovative cosmetic products. Furthermore, in addition to research and development, we will also provide consumers with information to maintain healthy skin, such as basic knowledge on UV rays and the impact of photoaging, etc. through seminars and symposiums.

Mr.Uotani, Mr.Shimatani of Shiseido, Dr. Fisher of CBRC and Dr.Slavin of MGH

Download Small Image[60.6KB] Download Large Image[476KB]

To celebrate the 30th anniversary of the CBRC and new six-year extension of the alliance, three representatives—Shiseido’s President and CEO Masahiko Uotani, Executive Vice President Yoichi Shimatani, and CBRC Director David E. Fisher, MD, PhD—gave comments as follows:


Shiseido’s President and CEO, Masahiko Uotani:
“In our quest to remain vital for the next 100 years and beyond, this year, we at Shiseido created a new corporate mission “BEAUTY INNOVATIONS FOR A BETTER WORLD.” Ongoing efforts to foster innovation is our responsibility and mission to make this world better through the power of beauty. The CBRC is an indispensable and important partner for Shiseido to create unprecedented, first-of-its-kind value and change the lives of people around the world. Let us cling together for the future and challenge for the innovation that surpasses society's expectations.”

Executive Vice President, Yoichi Shimatani:
“It has been 30 years since we began our partnership with the CBRC. We have delivered many outstanding research achievements, more than we had initially imagined, realizing ideal collaboration between laboratories in academia and a company. We will continue to create innovation with the CBRC, a state-of-the-art laboratory that symbolizes our open innovation activities.”

CBRC Director, David E. Fisher:
“The Shiseido-CBRC relationship is a source of immense pride to Dermatology at Mass General Hospital/Harvard Medical School. Close collaboration at the cutting edge of science is the shared mission, and numerous significant discoveries continue to be made through common efforts. We are proud to celebrate 30 years of important discoveries by our scientists working together, and look forward to continued progress in optimizing all aspects of skin health and wellbeing.”

About CBRC

The CBRC is a general research institute for advanced research and development in the field of dermatology established by Harvard Medical School and Massachusetts General Hospital with support from Shiseido in 1989. We started collaborative research 30 years ago and since then we have achieved many remarkable research results in skin and hair science. Many researchers have also been dispatched from Shiseido, contributing to the cultivation of global research talent.

For details, please refer to PDF.

*The content of the release is correct as of the time of release, but please note that it may in some cases differ from the latest information.